resistance to non-covalent btki’s
Published 10 months ago • 64 plays • Length 1:56Download video MP4
Download video MP3
Similar videos
-
3:10
understanding resistance mutations with covalent and non-covalent btkis
-
1:20
improving outcomes of non-covalent btki treatment
-
2:33
btki resistance and it's management
-
1:32
genomic evolution & resistance to pirtobrutinib in covalent btk inhibitor pre-treated cll
-
2:38
the role of covalent and non-covalent btkis in the mcl treatment landscape
-
1:21
overview of the role of non-covalent btk inhibitors in the era of covalent btk inhibitors
-
16:13
3mensio ct pre-case planning: valve-in-valve tavr in trifecta
-
49:10
topic 6 contouring - level iii and iv lymph nodes
-
4:44
mechanisms of tki resistance
-
2:52
acquired mutations associated with resistance to btki in patients with cll
-
2:23
non-covalent vs covalent btk inhibitors in cll
-
0:45
cys-ser mutation-driven ibrutinib resistance and alternative btki’s under development
-
2:20
genomic evolution and resistance to pirtobrutinib in cll: insights from the bruin study
-
0:48
advances in non-covalent btk inhibitors for cll: bruin study update
-
1:24
sequencing of btk inhibitors in cll
-
2:37
resistance to acalabrutinib in cll is mediated by btk mutations
-
1:07
current state of the field: non-covalent btk inhibitors for cll
-
2:16
the role of covalent btkis in the management of cll
-
1:06
an ongoing phase i trial evaluating as-1763, a novel non-covalent btki, in b-cell lymphomas
-
2:53
considering the sequencing of covalent and non-covalent btk inhibitors in cll
-
1:25
preliminary results from a phase ib trial of as-1763, a novel non-covalent btki, in cll/mcl
-
1:18
pirtobrutinib: the next generation of btk inhibitors